A 16-year-old boy with an erythroleukemia in blastic phase has been successfully treated with an intensive combination chemotherapy (DCNP+ACNU), an isogeneic bone marrow graft (1.2×1010 bone marrow cells from identical twin) and an active immunotherapy (cell wall skeleton of BCG and 10,000 rad irradiated autologous leukemic cells).
The complete remission was confirmed on 21st day after the grafting, and since then, the patient has been treated only with the active immunotherapy with no signs of relapse and/or immune deficiency for more than 8 months.
These events suggest that bone marrow graft may make it possible to overcome the refractoriness of some leukemias to conventional chemotherapy with widened possibilities for dosage-increment of chemotherapeutic agents and/or for some another combinations of them.
